1 / 34

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice. Jeff Allen, MD, FAAFP Chief of Health Programs, FBOP Michelle Williams, PharmD Lieutenant, USPHS Hepatitis/HIV Program Manager, FBOP Newton Kendig , MD RADM, Assistant Surgeon General, USPHS

candace-hanson
Download Presentation

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strategic Applications of HCV Guidelines:Putting Protease Inhibitors into Practice Jeff Allen, MD, FAAFP Chief of Health Programs, FBOP Michelle Williams, PharmD Lieutenant, USPHS Hepatitis/HIV Program Manager, FBOP Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP

  2. Faculty Disclosure “We do not have any relevant financial relationships with any commercial interests.”

  3. Educational Objectives At the end of this presentation, participants will be able to: • Discuss the Federal Bureau of Prisons Guidelines for the treatment of HCV with protease inhibitors. • Describe barriers to effective HCV treatment in the correctional setting. • Outline key decisions needed to implement an effective HCV treatment program in the correctional setting.

  4. HCV INFECTION~Clinical Importance~ • HCV identified late 1980’s. • 3.2 million Americans with chronic infx. • Genotypes identified 1994 – 1,2,3, (4,5,6-less common) • Genotype 1 most common in US (⅔ to ¾ of cases) • Natural history • 1/5 resolve spontaneously • 3/5 develop chronic infx but no sequelae • 1/5 with chronic infx develop cirrhosis / complications • More die from HCV now than from HIV (15,000 + / yr) • ½ of HCC deaths (@9K / yr) from HCV • Most common reason for liver transplant • Direct medical costs > $6.7 billion (2010-2019)

  5. HCV INFECTION~History of HCV treatment~ • 1991 – IFN alfa approved • < 10% SVR • 1998 – IFN alfa + RBV approved • 2001 - PegIFN introduced • Significant improvement in SVR rates combined with RBV • SVR for genotype 2 or 3=70-80%; for genotype 1 = 40-50%. • Less effective in high viral loads, African Americans, cirrhosis, HIV or HBV co-infx, IL28B genotype C/T or T/T, prior treatment failures.

  6. HCV Protease Inhibitors~General Considerations~ • FDA approved May 2011 • Boceprevir (VictrelisTM) and Telaprevir (IncivekTM) • AASLD published updated guideline November 2011 • BOP Guideline issued March 2012 • Mechanism of action: • Direct Acting Antiviral Agent inhibits HCV viral replication • Binds to protease enzyme and inhibits cleavage into mature viral forms • Similar mechanism to HIV protease inhibitors but different spectrum of antiviral activity and NOT interchangeable.

  7. HCV Protease Inhibitors~FDA Approved Indications~ • Treatment of chronic HCV, genotype 1 - Not approved for tx of other HCV genotypes • In combination with pegIFN+ RBV - Not approved for monotherapy • Treatment naïve or prior tx failures with pegIFN/RBV - Relapse, partial or null response. • Re-tx of null responders not studied with BOC • SVR rates for prior null responders < 30% to 40%

  8. HCV Protease Inhibitors~Clinical Benefit ~ • SVR rates ↑ 20 to 40% compared to pegIFN + RBV! • Overall (70-80%) • Treatment naïve (67-75%) • African-American (62%) • Advanced fibrosis (62%) • High viral load (74%) • Relapser (69 -88%) • Partial responder (40-59%) • Null responder (23-38% with telaprevir based tx) • HCV Protease Inhibitor Trials • Boceprevir – SPRINT 1/2; RESPOND 2 • Telaprevir – ADVANCE, ILLUMINATE, PROVE 1/2; REALIZE

  9. HCV Protease Inhibitors~ Clinical Challenges ~ • Viral Resistance • IFN / RBV do not produce resistance. • Viral mutations → Resistance to HCV PIs • Treatment failure = viral resistance. • 80% to 90% correlation. • Non-adherence → viral resistance. • Viral resistance appears to be class effect - Cannot switch from one HCV PI to another for tx failure.

  10. HCV Protease Inhibitors~ Clinical Challenges ~ • Complex Medication Regimens / Decision Points • Duration of treatment determined by 4 variables • HCV treatment history - Tx naïve vs. relapser vs. partial responder vs. null responder • Fibrosis stage - Compensated cirrhosis treated for 48 weeks • Which HCV PI is prescribed - Tx algorithm is different for each HCV PI • Response to treatment - a.k.a. Response Guided Therapy (RGT)

  11. Boceprevir

  12. Response Guided Therapy - Boceprevir~ 4 Treatment Tracks~ • 28 wks (total) • 4 weeks pegIFN+ RBV (DT) followed by 24 weeks of BOC + pegIFN + RBV (TT) • If tx naïve & RNA undetectable (-) at 8 & 24 wks • 36 weeks (total) • 4 wks DT + 32 wks TT • If prior relapser / partial responder & RNA (-) at 8 & 24 wks • 48 wks (total) • 4 wks DT + 32 wks TT + 12 wks DT • If txnaïve, prior relapseror partial responder AND • RNA (+) after week 8 but (-) after TW 24 • If & RNA (+) at 8 but (-) at 24 wks • 48 wks (total) – 4 wks DT + 44 wks TT • If compensated cirrhosis

  13. Response Guided Therapy - Boceprevir~ Discontinuation Rules*~ • Stop all HCV meds if HCV RNA is • ≥ 100 IU/ml at 12 wks or • detectable (+) at 24 wks or • ↑ by > 1 log10 above treatment nadir *a.k.a. – “Futility Rules”

  14. BOP Boceprevir Algorithm

  15. Telaprevir

  16. Response Guided Therapy - Telaprevir~Dose & Duration of Treatment~ • First 12 weeks • Triple Therapy with TVR + pegIFN + RBV • TVR dose = 750 mg (two 375 mg tabs) PO q 8 hr (+/- 1hr) • Each dose must be taken with 20 gm fat snack • pegIFN + RBV, standard dosing. • D/C all meds if RNA > 1,000 IU/ml at 4 or 12 weeks or > 1 log increase from treatment nadir • Continue pegIFN + RBV for 24 or 48 weeks (total) • 24 wks total if • Tx naïve or relapserAND • RNA undetectable at 4 & 12wks. • 48 wks total if • Treatment naïve or relapserAND • HCV RNA (+) but ≤ 1,000 at 4 and 12 wks & undetectable at 24 wks • Compensated cirrhosis or prior partial responder AND • HCV RNA ≤ 1,000 at 4 and 12 wks & undetectable at 24 wks

  17. Response Guided Therapy - Telaprevir~ Discontinuation Rules*~ • D/C all meds if HCV RNA is • > 1000 IU/ml at 4 or 12 weeks or • Detectable at 24 weeks or • Increased by > 1 log 10 above treatment nadir. *a.k.a. – “Futility Rules”

  18. BOP Telaprevir Algorithm

  19. HCV Protease Inhibitors~ Clinical Challenges ~ • Medication side effects • PegIFN and RBV side effects • Boceprevir (BOC) • Anemia • Dysgeusia • Telaprevir (TVR) • Anemia • Rash / Pruritus • GI / anorectal • Dysgeusia • Hyperuricemia

  20. HCV Protease Inhibitors~Disadvantages~ • Cost (FSS or FSR) • Boceprevir + pegIFN/RBV (PR) • PR 28 / BOC 24 = $23,000 • PR 36 / BOC 32 = $30,400 • PR 48 / BOC 32 = $32,500 • PR 48 / BOC 44 = $41,537 • Telaprevir + PR • TPV 12 / PR 24 = $39,400 • TPV 12 / PR 48 = $43,700

  21. Strategies for Implementing HCV Triple Therapy in the BOP~Patient Selection - Whom to treat?~ • HCV Genotype 1 with ≥ stage 2 fibrosis on liver biopsy • Prioritize higher stages of fibrosis, e.g. stages 3 & 4 • Consider / discuss deferring tx for lower stages of fibrosis, e.g. stage 2 – newer agents likely in 2 to 5 yrs. • No contraindications /exclusions. • Highly motivated and compliant. • Continuity of care for new intakes on triple tx. • With appropriate assessment following intake. • Prior null responders to DT considered on case-by-case basis.

  22. Boceprevir vs.Telaprevir ~Anecdotal criteria for choosing BOC~ • Comorbid medical conditions • Cardiovascular or metabolic conditions • E.g. known coronary heart disease, DM, hyperlipidemia, or hyperuricemia/gout • Telaprevir requires 20 gm fat snack 3x/day and increases uric acid levels; • Anorectal conditions • E.g. hemorrhoids, proctitis, diarrhea • increased incidence of anorectal symptoms with telaprevir • Dermatologic conditions • E.g. eczema, psoriasis • Increased incidence of rash with telaprevir. • Lower fibrosis score • E.g. stage 2/4 – more likely to meet criteria for shorter course of therapy • BOC is cheaper / more cost effective with shorter treatment durations. • Medication contraindications (CI) with telaprevir • e.g. atorvastatin is CI with telaprevir but “use with caution” in BOC.

  23. Boceprevir vs.Telaprevir ~Anecdotal criteria for choosing telaprevir~ • Short Course of BOC not indicated • Compensated cirrhosis or prior treatment failures with pegIFN/RBV • Prior null responders not studied in BOC trials. • Simpler TVR regimen could improve adherence; • Cost advantage with BOC is lost with longer BOC tx course. • Medication contraindications with BOC • e.g. carbamazepine, phenobarbital, and phenytoin are CI with BOC but labeled as “use with caution” with TVR. • Borderline acceptable hemoglobin levels • Hgb decreased but not at contraindicated levels • BOC studies used ESAs (erythropoietin stimulating agents) in up to 50% of cases whereas TVR studies did not use ESAs and discontinuation rates were similar).

  24. Strategies for Implementing HCV Triple Therapy in the BOP~Prescribing / Dispensing issues~ • HCV PIs must be taken q 8 hr (+/- 1 hr) with food • Continue BID pill line for RBV and weekly pegIFN injx as per current local procedures. • Dispense weekly supply of HCV PI • Inmate must return empty bottles / blisters each wk. • Remote fill – requested 1 week prior. • Treating clinician sends e-mail request for supplemental feeding (3 times / day) to FSA. • TVR – 20 gm fat snack (3 TBSP peanut butter or 2 slices cheese with bread or crackers) • BOC – taken with a meal or light snack, per policy.

  25. When and What Labs do I order?

  26. Is there a way to customize Monitoring Treatment of my Patient? Sample Lab Planner which can auto-populate dates due for labs based on treatment start date

  27. HCV RNA Viral Load Report Interpretation • HCV RNA schedule • Baseline, end of tx, & 24 wks after ETR • BOC – treatment weeks 4, 8, 12, 24 • TVR – treatment wks 4, 12, 24 • Report interpretation • Futility: > 1000 IU/ml wk 4 or wk 12 (TVR); or ≥ 100 IU/ml wk 12 (BOC). • Detectable vs. Undetectable • Timely drawing and result reporting is essential

  28. Strategies for Implementing HCV Triple Therapy in the BOP • Transfer issues • Place medical hold on patients during treatment to prevent treatment interruptions. • Patient education is essential • Treatment regimen and adherence • Side effects • Medication interactions / pregnancy issues • Option to postpone therapy if stage 2 fibrosis • Cannot transfer or release during treatment • Have patient sign Hep C tx consent form

  29. Team Medicine Approach:The Key Strategy • Utilizing a multidisciplinary team helps navigate the complexities of HCV treatment • BOP is utilizing Regional HCV Clinical Pharmacist Consultants to work in conjunction with health services staff at the local level to provide guidance on the new HCV protease inhibitors and optimize patient outcomes, while promoting cost efficiencies.

  30. BOP Experience to Date • Non-formulary requests approved for tx – 153 • 92 for boceprevir • 61 for telaprevir • 130 started on treatment; 98 active on tx; 17 completed tx (16 with ETR, 1 relapse) • 28 d/c’d; 8 due to virologic failure; 10 due to patient non-compliance or refusal; 10 due to hematologic factors (anemia, neutropenia, thrombocytopenia) despite INF/RBV dose adjustment • Too early to assess overall efficacy

  31. BOP Experience to Date • ETRs: BOC – 10/TVR – 11 • Virologic failures: BOC – 6/TVR – 5 • Discontinuance: BOC – 17/TVR - 13 • Hematologic - BOC – 8/TVR - 4

  32. BOP Experience to Date~Lessons Learned~ • Patient education / informed consent is critical • Tracking snack intake is important • Telaprevir requires uric acid monitoring • Lack of timely laboratory monitoring can be dangerous for the patient and costly when treatment fails • Major side effects noted: anemia, neutropenia, and rash • Quality control is absolutely critical as there are multiple ways of making mistakes in treatment regimen / monitoring.

  33. Issues for Correcttions in Treating HCV Genotype 1 in 2013 Treatment is very expensive – ensure guidelines and administrative controls are in place Treatment is extraordinarily complicated – consolidate treatment centers where feasible, implement algorithms/monitoring tools, and adopt quality control measures Await newer treatment options to include simpler, possible all oral regimens in the future Anticipate more personalized approach to treatment based on genetic host factors

  34. Questions ?

More Related